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Abstract 17 
OBJECTIVES 18 
In Klebsiella pneumoniae, loss of function mutations in the transcriptional repressors RamR 19 
and OqxR both have an impact on the production of efflux pumps and porins relevant to 20 
antimicrobial efflux/entry. Our aim was to define, in an otherwise isogenic background, the 21 
relative effects of OqxR and RamR loss of function mutations on envelope protein 22 
production, envelope permeability, and antimicrobial susceptibility. We have also 23 
investigated the clinical relevance of an OqxR loss of function mutation, particularly in the 24 
context of β-lactam susceptibility.  25 
METHODS 26 
Envelope permeability was estimated using a fluorescent dye accumulation assay. 27 
Antimicrobial susceptibility was measured using disc testing. Total envelope protein 28 
production was quantified using LC-MS/MS proteomics, and quantitative RT-PCR was used 29 
to measure transcript levels.  30 
RESULTS 31 
Loss of RamR or OqxR reduced envelope permeability in K. pneumoniae by 45-55% relative 32 
to wild-type. RamR loss activated AcrAB efflux pump production ≈5-fold, and this reduced 33 
β-lactam susceptibility, conferring ertapenem non-susceptibility even in the absence of a 34 
carbapenemase. In contrast, OqxR loss specifically activated OqxAB efflux pump production 35 
>10,000-fold. This reduced fluoroquinolone susceptibility but had little impact on β-lactam 36 
susceptibility even in the presence of a β-lactamase. 37 
CONCLUSIONS  38 
Whilst OqxR loss and RamR loss are both seen in K. pneumoniae clinical isolates, only RamR 39 
loss significantly stimulates AcrAB efflux pump production. This means that only RamR 40 
mutants have significantly reduced β-lactamase mediated β-lactam susceptibility and 41 
therefore represent a greater clinical threat.  42 
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Introduction 43 
Multiple envelope proteins contribute to antimicrobial susceptibility and resistance in 44 
Klebsiella pneumoniae. Two major porins, OmpK35 and OmpK36 are important for drug 45 
entry,1–4 and the OmpK35/36 ratio is affected by osmolarity.5 Drug efflux  is mainly catalysed 46 
by the Resistance Nodulation Cell Division (RND)-type pump, AcrB, working with AcrA and 47 
TolC as a tripartite system.6–8 AcrAB production is controlled by the transcriptional repressor 48 
AcrR and is upregulated following overproduction of the AraC-type transcriptional activator 49 
RamA.6,9,10 RamA overproduction also boosts transcription of micF, encoding an antisense 50 
RNA, which downregulates OmpK35 porin production, and RamA upregulates a second RND-51 
type efflux pump, OqxAB.10 RamA hyper-production occurs in ramR loss of function mutants 52 
because RamR is a transcriptional repressor of ramA.9-11 Loss of function mutations in the 53 
transcriptional repressor OqxR also activate oqxAB transcription, as well as transcription of 54 
rarA, which encodes a RamA orthologue.11,12 To add to this complexity, increased efflux pump 55 
and/or reduced porin production can confer an additive effect in combination with plasmid 56 
mediated antimicrobial resistance proteins or target site mutations. This has been 57 
demonstrated for the complex interplay of factors that influence ciprofloxacin susceptibility,13 58 
and in the generation of potentially important and perhaps clinically under-reported 59 
carbapenemase negative carbapenem resistance phenotypes.10,14 60 
We have previously characterise the interplay between factors that confer RamA mediated 61 
multi-drug resistance in K. pneumoniae.10 The aim of the work reported here was to analyse 62 
the importance of oqxR loss of function mutation in multi-drug resistance, and to identify the 63 
resistance proteins involved. 64 
 65 
Materials and Methods 66 
Bacterial strains and susceptibility testing  67 
Four K. pneumoniae strains were used in the study. Ecl8,15 plus in vitro selected loss of 68 
function mutants in oqxR (Tyr109STOP) or ramR (Thr124Pro)13 and finally, Ecl8ΔramR 16 69 
additionally carrying a gyrA QRDR (Ser83Phe) and an oqxR loss of function mutation 70 
(Arg93Cys).13 E. coli XL10-Gold (Stratagene) was used for cloning. Disc susceptibility testing 71 
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was performed according to CLSI methodology 17 and interpreted using CLSI performance 72 
standards.18 73 
Cloning genes, transformation and complementation studies 74 
The wild-type oqxR and ramR genes of K. pneumoniae Ecl8 were amplified by PCR using the 75 
primers listed in Table S1. Each PCR amplicon was TA cloned into pCR2.1-TOPO (Invitrogen) 76 
according to the manufacturer’s instructions. The inserts were removed using EcoRI (for oqxR) 77 
or HindIII plus XbaI (for ramR) and ligated into pK18.19 The rarA gene was PCR amplified from 78 
Ecl8 using primers listed in Table S1 and directly ligated into pBAD322K 20 after cutting with 79 
NcoI and XbaI. Cloning of plasmid-mediated β-lactamase genes blaCTX-M-1 and blaCMY-4 (with 80 
their native promoters) using the vector pSU18 10 and later sub-cloning into the vector pUBYT 81 
has previously been reported.14 Recombinant plasmids were used to transform K. 82 
pneumoniae strains to kanamycin (30 mg/L for pBAD322 and 50mg/L for pUBYT) using 83 
electroporation. All strains and plasmids are recorded in Table S2. 84 
Quantitative analysis of envelope proteome via Orbitrap LC-MS/MS and quantitative RT-PCR 85 
Each mutant and transformant was cultured in 50 mL Cation Adjusted Mueller-Hinton broth 86 
(MHB) (Sigma) with appropriate antibiotic selection. Cultures were incubated with shaking 87 
(160 rpm) at 37°C until the optical density at 600 nm reached 0.5-0.7. Total cellular RNA was 88 
purified and qRT-PCR was performed as previously described,10,21 using the primers listed in 89 
Table S1. Total envelope proteomics was performed as previously described.10,21 For each LC-90 
MS/MS proteomics experiment, raw protein abundance data were collected for three 91 
biological replicates of each test condition. A paired T-test was used to calculate the 92 
significance of any difference in protein abundance in pooled data from the two test 93 
conditions. A p-value of <0.05 was considered significant. The fold change in abundance for 94 
each protein in the two test conditions was calculated using the averages of absolute 95 
abundances for the three biological replicates for the two test conditions. 96 
Fluorescent Hoechst (H) 33342 dye accumulation assay 97 
Envelope permeability was estimated as described previously 21 in bacteria grown in MHB 98 
using an established fluorescent dye accumulation assay.22 The assay was performed using a 99 
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black, flat-bottomed 96-well plates (Greiner Bio-one, Stonehouse, UK) and a Fluostar Optima 100 
(Aylesbury, UK) plate reader. H33342 dye (Sigma) was used at a final concentration of 2.5 µM. 101 
 102 
Results and Discussion 103 
Relative impact of OqxR and RamR loss of function mutations on antimicrobial susceptibility 104 
and envelope permeability  105 
We have recently reported in vitro selection of oqxR and ramR loss of function mutants from 106 
the wild-type K. pneumoniae strain Ecl8.13 Table 1 reports the relative impacts of these 107 
mutations on inhibition zone diameter for a range of antimicrobials of different classes. As 108 
expected, the ramR point mutant phenotype was very similar to the profile seen for an 109 
Ecl8ΔramR mutant previously studied.10 The oqxR mutation had a larger effect on 110 
fluoroquinolone and chloramphenicol susceptibility than the ramR mutation (68 mm versus 111 
47 mm combined zone diameter reduction across five agents); the ramR mutation had a 112 
larger impact on cephalosporin susceptibility than the oqxR mutation (69 mm versus 46 mm 113 
combined zone diameter reduction across 10 agents). Both mutations conferred minocycline 114 
non-susceptibility though neither had any effect on the zone diameters around carbapenem 115 
or aminoglycoside discs. 116 
Overall envelope permeability (a combination of outer membrane permeability and efflux) in 117 
the two mutants was similar. The steady state accumulation of a fluorescent dye was ≈45% 118 
and ≈55% of wild-type for the ramR and oqxR mutants, respectively (Fig. 1).  119 
Efflux pump and porin protein abundance changes in oqxR and ramR mutants 120 
We used Orbitrap LC-MS/MS proteomics to define the impact of the ramR and oqxR 121 
mutations on the production of porins and efflux pumps previously implicated in 122 
antimicrobial drug resistance in K. pneumoniae. The OqxA and OqxB efflux pump proteins 123 
were found to be below the detection level in wild-type cells, but they were detectable in 124 
both the ramR and oqxR mutants, with upregulation being almost two orders of magnitude 125 
greater in the latter (Fig. 2c,d). By contrast, upregulation of AcrA and AcrB efflux pump 126 
proteins was only observed in the ramR mutant (Fig. 2a,b) with similar fold increases to those 127 
reported recently for an Ecl8ΔramR mutant (4.79- versus 3.88-fold for AcrA and 3.56- versus 128 
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4.87-fold for AcrB).10 Whist it has not been confirmed experimentally in K. pneumoniae, TolC 129 
is likely to work as the outer membrane protein for both OqxAB and AcrAB. TolC levels were 130 
significantly upregulated in both oqxR and ramR mutants relative to wild type (Fig. 2e). 131 
Downregulation of the OmpK35 porin was equally observed in both mutants: 0.43-fold, 132 
p=0.005 (oqxR mutant), 0.41-fold p=0.005 (ramR mutant) (Fig. 2f). Significant changes in 133 
abundance of the OmpK36 porin were not observed in either mutant (Fig. 2g). A list of 134 
proteins for which abundance was significantly changed (≥2-fold, p<0.05) in the oqxR or ramR 135 
mutant relative to Ecl8 during growth in MHB are shown in Table S3 and Table S4. Ten of 136 
eleven proteins previously shown to be significantly up-regulated ≥2-fold upon deletion of 137 
ramR in Ecl8, irrespective of growth conditions,10 were also regulated in the ramR point 138 
mutant; the only protein significantly down-regulated ≥2-fold in Ecl8ΔramR and the Ecl8 ramR 139 
point mutant was OmpK35 (Table S4). Twelve of 23 proteins differentially regulated in the 140 
oqxR loss of function mutant (Table S3) during growth in MHB were also differentially 141 
regulated in the ramR mutant (Table S4) when grown in the same conditions.  142 
To confirm the relative impacts of the oqxR and ramR mutations on efflux pump and porin 143 
production, we took a previously selected oqxR/ramR double mutant,13 and individually 144 
complemented either oqxR or ramR in trans. The double mutant produced levels of AcrAB 145 
similar to the ramR mutant and levels of OqxAB similar the oqxR mutant (Fig. 3 a,b,c,d; Fig. 2 146 
a,b,c,d). We found TolC or OmpK35 production to be maximally altered in the oqxR or ramR 147 
single mutants because protein levels were similar in the oqxR/ramR double mutant to levels 148 
in the oqxR or ramR single mutants (Fig. 3 e,f,g; Fig. 2 e,f,g). However, the additive effect of 149 
the two regulatory mutations on AcrB/OqxB efflux pump protein production was enough to 150 
further reduce envelope permeability to ≈25% of wild-type, according to the fluorescent dye 151 
accumulation assay (Fig. S1). This is because, in protein abundance terms, AcrB and OqxB are 152 
limiting (Fig. 2). Complementation of either ramR or oqxR in the double mutant increased 153 
envelope permeability to ≈55% of wild-type (Fig. S1), the level of permeability seen in the 154 
single mutants (Fig. 1), confirming that there are no other significant factors involved. 155 
Likewise, complementation of the double mutant with either oqxR or ramR resulted in a 156 
recombinant that produced efflux pump and porin proteins as expected given the remaining 157 
mutation (Fig. 3 a,b,c,d; Fig. 2 a,b,c,d). 158 
Impact of RarA overproduction in the oqxR mutant 159 
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We have shown that oqxR loss has a large impact on OqxAB but no significant (p>0.05) impact 160 
on AcrAB abundance (Fig. 2). This would fit with OqxR being a local transcriptional repressor 161 
of oqxAB, as previously demonstrated.11,12 However, loss of oqxR significantly upregulates 162 
TolC and reduces levels of OmpK35 (Fig. 2). It has previously been shown that OqxR controls 163 
transcription of rarA,12 encoding a RamA-like global transcriptional activator.23 Accordingly, 164 
we hypothesised that the wider effects of oqxR loss in Ecl8 were caused by overexpression of 165 
rarA. qRT-PCR revealed that rarA expression is indeed upregulated (417 + 127-fold) in the 166 
oqxR mutant. Expression of acrA does not significantly change (1.4 + 0.1-fold) in the oqxR 167 
mutant, as predicted from the proteomics (Fig. 2). 168 
In order to dissect out the implications of RarA overproduction on the proteomic changes 169 
seen in the oqxR mutant, we cloned rarA without its promoter into pBAD322K 20 and set about 170 
overexpressing it by using arabinose induction. qRT-PCR confirmed rarA expression in 171 
Ecl8(pBAD322K:rarA) in the presence of 0.02% w/v arabinose was very similar (415 + 87.2 fold 172 
more than control) to that seen in the oqxR mutant. Key efflux and porin protein production 173 
levels following rarA overexpression at this level (Fig. S2) were very similar to those seen in 174 
the ramR loss of function mutant (Fig. 2) in which ramA, a close homologue of rarA, is 175 
overexpressed.10 176 
Based on the phenotype of the Ecl8 oqxR mutant (Fig. 2), the very different impact of rarA 177 
overexpression on protein levels in Ecl8 (Fig. S2) was surprising. Whilst rarA expression was 178 
the same in the oqxR loss of function mutant and in the rarA over-expressing, oqxR wild-type 179 
recombinant (see above), increased AcrAB production was only seen in the rarA over-180 
expressing, oqxR wild-type recombinant (Fig 2, S2). The positive impact of rarA 181 
overexpression on acrAB expression in an oqxR wild-type background has also been reported 182 
by others.12 We hypothesise that RarA preferentially binds to the oqxAB promoter, so when 183 
OqxR is not present – in the oqxR mutant – the overproduced RarA predominantly drives 184 
oqxAB expression, and there is little impact on acrAB expression. However, when RarA is 185 
overproduced in a background when OqxR is located as a repressor on the oqxAB promoter 186 
(an artificial situation unlikely ever to be seen in a clinical isolate) RarA binds at less 187 
preferential sites, including the acrAB promoter. 188 
Impact of OqxR loss of function in combination with plasmid mediated cephalosporinases on 189 
carbapenem susceptiblity   190 
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We have recently shown that ramR loss of function enhances the impact of carrying the serine 191 
active site cephalosporinases blaCTX-M-1 and blaCMY-4, with particularly worrying effects on 192 
carbapenem susceptibility, including causing ertapenem resistance in some cases.10,14 To see 193 
whether OqxR loss has a similar impact, plasmids encoding blaCTX-M-1 or blaCMY-4, were used to 194 
transform our Ecl8 oqxR point mutant. There was a very slight impact on ertapenem 195 
susceptibility in comparison with Ecl8 transformants (Table S5), but much less than that seen 196 
previously in an Ecl8ΔramR mutant.10 This probably reflects the relatively low impact of oqxR 197 
loss on β-lactam susceptibility (Table 1), because of its negligible impact on AcrAB efflux pump 198 
production (Fig. 2) and the fact that OqxAB is not a noted β-lactam efflux pump.24 199 
PCR sequencing was used to identify oqxR mutations in a collection of 44 K. pneumoniae 200 
clinical isolates where ramR sequence and β-lactamase complement had already been 201 
determined.10 All oqxR mutants were confirmed to hyper-produce OqxAB using LC-MS/MS 202 
proteomics of whole cell extracts as previously described.13 As expected from our work with 203 
Ecl8 transformants (Table S5), there was no impact of the oqxR loss of function mutation on 204 
carbapenem susceptibility in isolates M and AD, which carry blaCTX-M-15, though, as previously 205 
noted, loss of ramR causes ertapenem resistance in blaCTX-M-15 carrying isolate T (Table S6).10 206 
Conclusion  207 
It is known that oqxR loss of function causes oqxAB over-expression, and this is associated 208 
with tigecycline resistance.12,25,26 It is also known that rarA is overexpressed, and that when 209 
overproduced in a recombinant form, RarA can have a wide range of effects on the cell, 210 
including upregulation of acrAB and tolC transcription.21,23 However, our use of proteomics 211 
has allowed the first analysis of the relative impact of these events on the abundance of efflux 212 
pump and porin proteins in K. pneumoniae and has allowed us to define the relative 213 
importance of oqxR and ramR loss of function mutations, which can both be found in clinical 214 
K. pneumoniae isolates.13 Loss of OqxR has a dramatic effect on OqxAB efflux pump 215 
production, with the absolute abundance of OqxB in an oqxR mutant being similar to that of 216 
AcrB (≈2 x109 units) (Fig. 2). The impact of this >10,000-fold upregulation of OqxAB on 217 
antimicrobial susceptibility is rather modest, however (Table 1). There is strong effect on 218 
fluoroquinolone susceptibility, conferring ciprofloxacin resistance in the presence of other 219 
mechanisms.13 OqxAB overproduction also causes chloramphenicol, minocycline  and, 220 
reportedly, tigecycline resistance (Table 1),25,26 but its overall impact on β-lactam 221 
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susceptibility is low, even in the presence of a plasmid mediated cephalosporinase (Table 1, 222 
S5,  S6). This limits the clinical importance of oqxR loss relative to ramR loss and is likely to be 223 
because there is a negligible effect of oqxR loss on AcrAB production (Fig. 2). Indeed, when 224 
AcrAB is overproduced only ≈5-fold more than wild-type levels, as seen in a ramR mutant, this 225 
confers ertapenem resistance in the presence of a cephalosporinase.10 Our work here also 226 
adds support to our hypothesis that OmpK35 downregulation is not particularly important for 227 
reducing β-lactam susceptiblity,10 since OqxR loss and RamR loss both cause a similar 228 
downregulation of OmpK35 (Fig. 2) but very different effects on β-lactam susceptibility (Table 229 
1, S5, S6). 230 
We were slightly surprised that oqxR loss does not cause AcrAB upregulation, because it has 231 
previously been shown that oqxR loss causes rarA over-expression,12 and that RarA 232 
overproduction from a recombinant system in an oqxR wild-type background causes AcrAB 233 
upregulation.12,23 Whilst we were able to reproduce these previous findings (Fig. S2), the key 234 
here is that RarA overproduction in an OqxR wild-type background, as used previously to 235 
define the rarA regulon 23  is not relevant to what happens in an oqxR loss of function mutant. 236 
The impact of RarA overproduction is less broad in an oqxR mutant because it predominantly 237 
acts as a positive feed-forward mechanism to dramatically activate oqxAB transcription, 238 
explaining the >10,000-fold upregulation of OqxAB production seen (Fig. 2) rather than taking 239 
on a highly pleotropic role. Nonetheless, RarA overproduction does have additional effects in 240 
the cell, even when overproduced due to oqxR loss, and many of the genes controlled are also 241 
controlled by RamA (Table S3). 242 
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Table 1: Disc susceptibility testing for K. pneumoniae Ecl8 and its ramR and oqxR mutants 327 
Antibiotic disc  
(µg in disc) 
Diameter of growth inhibition zone (mm) around antibiotic 
disc, or difference in zone diameter relative to control  
Ecl8 ramR oqxR 
Ciprofloxacin (5) 37 -12 -15 
Norfloxacin (10) 33 -9 -14 
Ofloxacin (5) 31 -9 -11 
Levofloxacin (5) 33 -8 -10 
Chloramphenicol (30) 29 -9 -18 
Cefotaxime (30) 37 -7 -4 
Ceftizoxime (30) 36 -4 -2 
Cephalothin (30) 25 -8 -5 
Cefoxitin (30) 33 -13 -11 
Cefotetan (30) 29 -3 NC 
Cefuroxime (30) 30 -11 -9 
Ceftazidime (30) 35 -7 -5 
Ceftriaxone (30) 35 -6 -5 
Cefoperazone (75) 32 -7 -5 
Cefepime (30) 32 -3 NC 
Aztreonam (30) 35 -3 -3 
Imipenem (10) 27 NC NC 
Meropenem (10) 30 NC NC 
Doripenem (10) 27 NC NC 
Ertapenem (10) 29 NC NC 
Minocycline (30) 22 -10 -7 
Tetracycline (30) 26 -6 -5 
Tigecycline (15) 20 -5 -3 
Amikacin (30) 25 NC NC 
Gentamicin (10) 23 NC NC 
Tobramycin (10) 23 NC NC 
Kanamycin (30) 23 NC NC 
 328 
Values reported are the means of three repetitions rounded to the nearest integer. Zone 329 
diameters are reported for Ecl8; difference from the Ecl8 values are reported for the ramR or 330 
oqxR loss of function mutants. NC means no change in zone diameter relative to Ecl8. Shading 331 
represents non-susceptibility (resistance or intermediate resistance) according to breakpoints 332 
set by the CLSI.18  333 
  334 
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Figure Legends 335 
 336 
Figure 1: The accumulation of H33342 dye over a 30 cycle (45 minute) incubation period by 337 
K. pneumoniae oqxR and ramR mutants relative to Ecl8 wild-type. In each case, fluorescence 338 
of mutant cells incubated with the dye is presented relative to wild type Ecl8 cells (set to 339 
100%) after each cycle. Each line shows mean data for three biological replicates with 8 340 
technical replicates in each. Error bars define the standard error of the mean. 341 
 342 
Figure 2: Abundance of key envelope proteins in K. pneumoniae Ecl8 wild-type and the oqxR 343 
and ramR mutants measured using LC-MS/MS proteomics. Values reported are absolute 344 
abundance values (x10-7, arbitrary units) recorded by the instrument used. Data are means 345 
(n=3 biological replicates) error bars are standard error of the mean. Stars (*) above a bar 346 
indicate a significant difference in abundance relative to control based on the following rules: 347 
fold difference in abundance is > 2 and p<0.05 for a T-test comparing absolute protein 348 
abundance data, n=3. 349 
 350 
Figure 3: Envelope proteome changes in complemented mutants; ∆ramR+oqxR::pk18(oqxR) 351 
and ∆ramR+oqxR::pk18(ramR) in comparison with plasmid-only control. Values reported 352 
are absolute abundance values (x10-7, arbitrary units) recorded by the instrument used. Data 353 
are means (n=3 biological replicates) error bars are standard error of the mean. Stars (*) 354 
above a bar indicate a significant difference in abundance relative to control based on the 355 
following rules: fold difference in abundance is > 2 and p<0.05 for a T-test comparing absolute 356 
protein abundance data, n=3. 357 
 358 
 359 
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Figure 1 361 
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Figure 3. 376 
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